Literature DB >> 35417719

Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes.

Anna Köferle1, Andreas Schlattl1, Alexandra Hörmann1, Venu Thatikonda1, Alexandra Popa1, Fiona Spreitzer1, Madhwesh C Ravichandran1, Verena Supper1, Sarah Oberndorfer1, Teresa Puchner1, Corinna Wieshofer1, Maja Corcokovic1, Christoph Reiser1, Simon Wöhrle1, Johannes Popow1, Mark Pearson1, Javier Martinez2, Stefan Weitzer2, Barbara Mair3, Ralph A Neumüller4.   

Abstract

Genetic networks are characterized by extensive buffering. During tumor evolution, disruption of functional redundancies can create de novo vulnerabilities that are specific to cancer cells. Here, we systematically search for cancer-relevant paralog interactions using CRISPR screens and publicly available loss-of-function datasets. Our analysis reveals >2,000 candidate dependencies, several of which we validate experimentally, including CSTF2-CSTF2T, DNAJC15-DNAJC19, FAM50A-FAM50B, and RPP25-RPP25L. We provide evidence that RPP25L can physically and functionally compensate for the absence of RPP25 as a member of the RNase P/MRP complexes in tRNA processing. Our analysis also reveals unexpected redundancies between sex chromosome genes. We show that chrX- and chrY-encoded paralogs, such as ZFX-ZFY, DDX3X-DDX3Y, and EIF1AX-EIF1AY, are functionally linked. Tumor cell lines from male patients with loss of chromosome Y become dependent on the chrX-encoded gene. We propose targeting of chrX-encoded paralogs as a general therapeutic strategy for human tumors that have lost the Y chromosome.
Copyright © 2022 Boehringer Ingelheim RCV GMBH & Co KG. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CP: Cancer; DDX3X; DDX3Y; RPP25; RPP25L; cancer; genetic interaction; loss of chromosome Y; paralog; sex chromosomes; synthetic lethality

Mesh:

Substances:

Year:  2022        PMID: 35417719     DOI: 10.1016/j.celrep.2022.110636

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  2 in total

1.  Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.

Authors:  Birgit Wilding; Dirk Scharn; Dietrich Böse; Anke Baum; Valeria Santoro; Paolo Chetta; Renate Schnitzer; Dana A Botesteanu; Christoph Reiser; Stefan Kornigg; Petr Knesl; Alexandra Hörmann; Anna Köferle; Maja Corcokovic; Simone Lieb; Guido Scholz; Jens Bruchhaus; Markus Spina; Josef Balla; Biljana Peric-Simov; Jasmin Zimmer; Sophie Mitzner; Thomas N Fett; Alexandra Beran; Lyne Lamarre; Thomas Gerstberger; Daniel Gerlach; Markus Bauer; Andreas Bergner; Andreas Schlattl; Gerd Bader; Matthias Treu; Harald Engelhardt; Stephan Zahn; Julian E Fuchs; Johannes Zuber; Peter Ettmayer; Mark Pearson; Mark Petronczki; Norbert Kraut; Darryl B McConnell; Flavio Solca; Ralph A Neumüller
Journal:  Nat Cancer       Date:  2022-07-26

2.  Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway.

Authors:  Meng-Hui Zhang; Jun Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.